Scholarlink

<p>Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, high-grade, neuroendocrine carcinoma with an aggressive clinical course, and there are few treatment options for relapsed and refractory cases. Tarlatamab, a first-in-class, bispecific T-cell engager targeting delta-like ligand 3 (DLL3) and CD3, holds promise as a therapeutic option for previously treated cases of small-cell lung cancer, but clinical data on LCNEC are exiguous. We report herein a 69-year-old, male patient. He underwent a left upper lobe partial resection for stage pT1bN0M0 LCNEC. Three years later, a recurrence with left pleural thickening, multiple liver metastases, and a marked elevation of pro-gastrin-releasing peptide developed. The patient had received five lines of systemic therapy over 2.5&#xa0;years. Comprehensive genomic profiling revealed a high tumor mutational burden but no actionable targets. With approval from the institutional ethics committee, tarlatamab therapy was begun as sixth-line therapy. The patient experienced manageable grade 1 cytokine release syndrome. After two cycles, computed tomography demonstrated a partial response with a 40% reduction in the sum of target lesion diameters (130&#xa0;mm to 78&#xa0;mm), and the pro-gastrin-releasing peptide level decreased from 1610&#xa0;ng/mL to 49.7&#xa0;ng/mL. The patient has received nine cycles of tarlatamab over eight months, and the response has persisted during this period without any serious adverse events. The findings of the present case suggest that tarlatamab has the potential to induce a meaningful and durable response in pretreated LCNEC and support further clinical evaluation of DLL3-targeted, T-cell-engaging therapy for this disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A case of Large Cell Neuroendocrine Carcinoma (LCNEC) treated with tarlatamab

  • 期刊论文

  • 发表日期：

    2026年7月1日

查看全文
  • Reimi Mizushima,
  • Makiko Yomota,
  • Satoko Togashi,
  • Terufumi Kato,
  • Yukio Hosomi

摘要

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, high-grade, neuroendocrine carcinoma with an aggressive clinical course, and there are few treatment options for relapsed and refractory cases. Tarlatamab, a first-in-class, bispecific T-cell engager targeting delta-like ligand 3 (DLL3) and CD3, holds promise as a therapeutic option for previously treated cases of small-cell lung cancer, but clinical data on LCNEC are exiguous. We report herein a 69-year-old, male patient. He underwent a left upper lobe partial resection for stage pT1bN0M0 LCNEC. Three years later, a recurrence with left pleural thickening, multiple liver metastases, and a marked elevation of pro-gastrin-releasing peptide developed. The patient had received five lines of systemic therapy over 2.5 years. Comprehensive genomic profiling revealed a high tumor mutational burden but no actionable targets. With approval from the institutional ethics committee, tarlatamab therapy was begun as sixth-line therapy. The patient experienced manageable grade 1 cytokine release syndrome. After two cycles, computed tomography demonstrated a partial response with a 40% reduction in the sum of target lesion diameters (130 mm to 78 mm), and the pro-gastrin-releasing peptide level decreased from 1610 ng/mL to 49.7 ng/mL. The patient has received nine cycles of tarlatamab over eight months, and the response has persisted during this period without any serious adverse events. The findings of the present case suggest that tarlatamab has the potential to induce a meaningful and durable response in pretreated LCNEC and support further clinical evaluation of DLL3-targeted, T-cell-engaging therapy for this disease.